LIQUID BIOPSY MARKET ANALYSIS

Liquid Biopsy Market, By Biomarker Type (CTC (Circulating Tumor Cells), ctNA (Circulating Tumor Nucliec Acids), Exosomes), By Sample Type (Blood, Urine, Others), By Disease Indication (Lung Cancer, Gastrointestinal Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Others), By End User (Hospitals, Cancer Institutes, Academic Institutes, Diagnostic Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Feb 2020
Code : CMI1223
Pages :180
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market Challenges And Opportunities

Global Liquid Biopsy Market: Drivers

Increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

Moreover, increasing funding for R&D in cancer is also expected to aid in growth of the market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.

Global Liquid Biopsy Market: Restraints

Levels of circulating free DNA (cfDNA) in serum and plasma vary. Such changes in cfDNA levels among patients may lead to inaccurate or unreliable test results in liquid biopsy, thereby hindering growth of the global liquid biopsy market.

Moreover, high cost of liquid biopsy is also expected to hinder growth of the market. Various expenses associated with liquid biopsy include cost of equipment & reagents and labor & professional costs.

Global Liquid Biopsy Market: Opportunities

Microfluidics is characterized by the precise manipulation of fluid within sub-millimeter channels. Many researches are ongoing for the development of lab-on-a-chip devices for biochemical analyses such as cell separation, DNA and protein analyses, and PCR amplification.

Moreover, adoption of cfDNA to monitor tumor alterations and tumor progression is expected to offer lucrative growth opportunities for players in the market.